Cargando…

Exploiting RIG-I-like receptor pathway for cancer immunotherapy

RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible gene 1 (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yangfu, Zhang, Hongying, Wang, Jiao, Chen, Jinzhu, Guo, Zeyu, Liu, Yongliang, Hua, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906624/
https://www.ncbi.nlm.nih.gov/pubmed/36755342
http://dx.doi.org/10.1186/s13045-023-01405-9
_version_ 1784884020276887552
author Jiang, Yangfu
Zhang, Hongying
Wang, Jiao
Chen, Jinzhu
Guo, Zeyu
Liu, Yongliang
Hua, Hui
author_facet Jiang, Yangfu
Zhang, Hongying
Wang, Jiao
Chen, Jinzhu
Guo, Zeyu
Liu, Yongliang
Hua, Hui
author_sort Jiang, Yangfu
collection PubMed
description RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible gene 1 (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) that have distinctive features. These receptors not only recognize RNA intermediates from viruses and bacteria, but also interact with endogenous RNA such as the mislocalized mitochondrial RNA, the aberrantly reactivated repetitive or transposable elements in the human genome. Evasion of RLRs-mediated immune response may lead to sustained infection, defective host immunity and carcinogenesis. Therapeutic targeting RLRs may not only provoke anti-infection effects, but also induce anticancer immunity or sensitize “immune-cold” tumors to immune checkpoint blockade. In this review, we summarize the current knowledge of RLRs signaling and discuss the rationale for therapeutic targeting RLRs in cancer. We describe how RLRs can be activated by synthetic RNA, oncolytic viruses, viral mimicry and radio-chemotherapy, and how the RNA agonists of RLRs can be systemically delivered in vivo. The integration of RLRs agonism with RNA interference or CAR-T cells provides new dimensions that complement cancer immunotherapy. Moreover, we update the progress of recent clinical trials for cancer therapy involving RLRs activation and immune modulation. Further studies of the mechanisms underlying RLRs signaling will shed new light on the development of cancer therapeutics. Manipulation of RLRs signaling represents an opportunity for clinically relevant cancer therapy. Addressing the challenges in this field will help develop future generations of cancer immunotherapy.
format Online
Article
Text
id pubmed-9906624
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99066242023-02-08 Exploiting RIG-I-like receptor pathway for cancer immunotherapy Jiang, Yangfu Zhang, Hongying Wang, Jiao Chen, Jinzhu Guo, Zeyu Liu, Yongliang Hua, Hui J Hematol Oncol Review RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible gene 1 (RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2) that have distinctive features. These receptors not only recognize RNA intermediates from viruses and bacteria, but also interact with endogenous RNA such as the mislocalized mitochondrial RNA, the aberrantly reactivated repetitive or transposable elements in the human genome. Evasion of RLRs-mediated immune response may lead to sustained infection, defective host immunity and carcinogenesis. Therapeutic targeting RLRs may not only provoke anti-infection effects, but also induce anticancer immunity or sensitize “immune-cold” tumors to immune checkpoint blockade. In this review, we summarize the current knowledge of RLRs signaling and discuss the rationale for therapeutic targeting RLRs in cancer. We describe how RLRs can be activated by synthetic RNA, oncolytic viruses, viral mimicry and radio-chemotherapy, and how the RNA agonists of RLRs can be systemically delivered in vivo. The integration of RLRs agonism with RNA interference or CAR-T cells provides new dimensions that complement cancer immunotherapy. Moreover, we update the progress of recent clinical trials for cancer therapy involving RLRs activation and immune modulation. Further studies of the mechanisms underlying RLRs signaling will shed new light on the development of cancer therapeutics. Manipulation of RLRs signaling represents an opportunity for clinically relevant cancer therapy. Addressing the challenges in this field will help develop future generations of cancer immunotherapy. BioMed Central 2023-02-08 /pmc/articles/PMC9906624/ /pubmed/36755342 http://dx.doi.org/10.1186/s13045-023-01405-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Jiang, Yangfu
Zhang, Hongying
Wang, Jiao
Chen, Jinzhu
Guo, Zeyu
Liu, Yongliang
Hua, Hui
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
title Exploiting RIG-I-like receptor pathway for cancer immunotherapy
title_full Exploiting RIG-I-like receptor pathway for cancer immunotherapy
title_fullStr Exploiting RIG-I-like receptor pathway for cancer immunotherapy
title_full_unstemmed Exploiting RIG-I-like receptor pathway for cancer immunotherapy
title_short Exploiting RIG-I-like receptor pathway for cancer immunotherapy
title_sort exploiting rig-i-like receptor pathway for cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906624/
https://www.ncbi.nlm.nih.gov/pubmed/36755342
http://dx.doi.org/10.1186/s13045-023-01405-9
work_keys_str_mv AT jiangyangfu exploitingrigilikereceptorpathwayforcancerimmunotherapy
AT zhanghongying exploitingrigilikereceptorpathwayforcancerimmunotherapy
AT wangjiao exploitingrigilikereceptorpathwayforcancerimmunotherapy
AT chenjinzhu exploitingrigilikereceptorpathwayforcancerimmunotherapy
AT guozeyu exploitingrigilikereceptorpathwayforcancerimmunotherapy
AT liuyongliang exploitingrigilikereceptorpathwayforcancerimmunotherapy
AT huahui exploitingrigilikereceptorpathwayforcancerimmunotherapy